1 week Ago By ABMN Staff
Gallacher Capital Management LLC grew its stake in shares of Collegium Pharmaceutical, Inc. ( NASDAQ:COLL – Free Report ) by 62.2% in the second quarter, HoldingsChannel.
com reports. The firm owned 9,338 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,582 shares during the period. Gallacher Capital Management LLC’s holdings in Collegium Pharmaceutical were worth $301,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in COLL. Gladius Capital Management LP bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $32,000. Principal Securities Inc.
bought a new position in shares of Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. nVerses Capital LLC grew its holdings in shares of Collegium Pharmaceutical by 1,600.0% in the second quarter.
nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares in the last quarter. Assetmark Inc. grew its holdings in shares of Collegium Pharmaceutical by 25.
5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,108 shares in the last quarter.
Finally, Sheaff Brock Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $204,000. Collegium Pharmaceutical Price Performance Collegium Pharmaceutical stock opened at $37.19 on Monday.
Collegium Pharmaceutical, Inc. has a 12 month low of $20.95 and a 12 month high of $40.
95. The company has a current ratio of 1.11, a quick ratio of 1.
04 and a debt-to-equity ratio of 1.71. The business’s 50 day simple moving average is $35.
01 and its 200 day simple moving average is $35.38. The company has a market cap of $1.
22 billion, a price-to-earnings ratio of 15.50 and a beta of 0.94.
Insiders Place Their Bets In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.
30, for a total transaction of $737,198.40. Following the sale, the executive vice president now owns 120,161 shares in the company, valued at $4,602,166.
30. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink . Company insiders own 3.
98% of the company’s stock. Analysts Set New Price Targets Several equities analysts have recently issued reports on the company. Truist Financial upped their target price on Collegium Pharmaceutical from $40.
00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th.
StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their target price for the company from $41.
00 to $44.00 in a report on Friday, June 7th. Finally, HC Wainwright upped their target price on Collegium Pharmaceutical from $47.
00 to $50.00 and gave the company a “buy” rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock.
Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $42.60. Check Out Our Latest Stock Report on Collegium Pharmaceutical About Collegium Pharmaceutical ( Free Report ) Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. See Also Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc.
( NASDAQ:COLL – Free Report ). Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter .
.
